Full Press Release Details
Oncolytics Biotech to Present at the Phacilitate
Immuno-Oncology Frontiers Conference
Dr. Andres Gutierrez, Oncolytics'
Chief Medical Officer, to present on the clinical progress and robust safety findings of using reovirus as an immuno-oncology viral
agent to treat cancer
CALGARY and SAN DIEGO, Sept. 19, 2017 /CNW/ - Oncolytics Biotech
Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN , a first-in-class,
intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced that it will
present at the Phacilitate Immuno-Oncology Frontiers Conference. Dr. Andres Gutierrez, Oncolytics' Chief Medical Officer,
will present at 4:00 pm CEST on September 21, 2017 at the Maritim Proarte Hotel. The conference takes place on September 20th and
21st in Berlin, Germany.
Dr. Gutierrez will highlight the role of REOLYSIN in the activation
of the immune system and the induction of an inflamed tumor phenotype in the tumor microenvironment. His presentation will
also review certain historical clinical programs, highlight the positive survival data from the IND 213 study in metastatic breast
cancer (mBC) and the pooled safety database - the largest of any oncolytic virus.
"We want to share our extensive experience with REOLYSIN
in the clinic to illustrate the specific expertise and efforts required to develop an oncolytic virus for intravenous administration
and systemic exposure in oncology," said Dr. Gutierrez. "This experience helped us define a clear regulatory pathway
for registration in metastatic breast cancer. With an overall agreement with the FDA on the phase 3 study design, details of the
pivotal registration study will be made available following evaluation and completion of discussions with clinical advisors and
potentially partners, as well as European regulators."
The Phacilitate Immuno-Oncology Frontiers conference hosts
over 300 industry decision-makers and key external stakeholders to come together discuss and define a strategic roadmap to success
for immuno-oncology developers, ensuring European patients gain access to the game-changing biotherapeutics of tomorrow. Immuno-Oncology
frontiers Berlin is the only European event that offers extensive coverage of the latest emerging science whilst placing it in
its wider strategic context as the basis of tomorrow's successful business and commercialisation models.
REOLYSIN is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered
immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis
and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing REOLYSIN, an intravenously delivered immuno-oncolytic virus. The compound induces
selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety
of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor
lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator (IMiD) combinations to facilitate
innate immune responses. Oncolytics is currently planning its first registration study in metastatic breast cancer, as well
as studies in combination with checkpoint inhibitors as well as targeted and IMiD therapies in solid and hematological malignancies. For
further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the
success of its research and development programs in 2017 and beyond, the Company's planned operations, the value of the additional
patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's
expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs;
and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks
and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development
projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the
Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals,
uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties
relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.
The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
View original content: http://www.newswire.ca/en/releases/archive/September2017/19/c8388.html
For further information: Investor Relations & Company
Contact: Michael Moore, Vice President, Investor Relations & Corporate Communications, 858-886-7813, mmoore@oncolytics.ca;
Media Contact: Mark Corbae, Canale Communications, (619) 849-5375, mark@canalecomm.com
CO: Oncolytics Biotech Inc.
CNW 07:00e 19-SEP-17